Dan

Dan, on behalf of Bob Huang, asked about the drivers of Global Lifestyle's high single-digit earnings growth for 2026, specifically how much would come from new partnerships or policies versus margin improvements. He also inquired about Assurant's long-term aspirations for the home warranty product line, including its growth and earnings profile, and its potential impact on Connected Living's overall earnings or margin profile.

Answer

CEO Keith Demmings outlined major drivers for Lifestyle's growth: continued mobile device protection subscriber growth (following 2 million increases in 2025), optimization of new programs and scaling of investments made in 2024 and 2025, sustained momentum in Global Automotive from rate increases and claims work, and broad expense discipline. For home warranty, CEO Keith Demmings stated aspirations to be the market leader, defining and growing the category rather than just taking share. CFO Keith Meier added that the home warranty business has a good long-term margin profile and is expected to become a meaningful contributor over time, similar to other Global Lifestyle businesses.

Dan asked Sridhar Ramaswamy to frame the impact of migrations on product revenue this quarter compared to the previous quarter, and to comment on the sustainability and visibility of this momentum. He also asked Brian Robbins about the Q4 operating margin guidance, noting it was lower than Q3 and implied in the prior quarter's guidance.

Answer

Sridhar Ramaswamy, CEO, indicated that Snowflake is 'super early' in legacy migrations, with AI acting as both a 'pull' (increasing data value) and a 'push' (accelerating migration processes), aided by acquisitions like Datometry. Brian Robbins, CFO, advised against over-interpreting the Q4 operating margin guidance, as it is provided concurrently with the annual guidance.

The analyst, speaking on behalf of Yi, inquired about the projected number of GMP manufacturing customers by the end of 2024, the pipeline beyond the currently disclosed customers, the expected test volume for the TR8 pharmacogenomic service, and plans for expansion into other states.

Answer

The company clarified that since the GMP facility launches at the end of fiscal 2024, the first GMP manufacturing runs are expected in early calendar 2025, with verbal commitments for about half of the capacity already secured. For the TR8 PGx service, they are initially targeting the concierge physician market in New York to build volume before pursuing larger enterprise contracts in H1 2025. They are also completing registration to sell in 47 additional states, which does not require the same lengthy validation process as New York.

Asked about future combination strategies, timing of the interim data, expectations for the NET program, peak sales potential for FYARRO, and historical trial data.

Answer

The company stated it's too early to discuss future combinations, the data is expected "later in Q3", they hope to see better ORR in the NET trial than historical mTORs, FYARRO growth will be incremental in a very rare indication, and provided details on historical trial data.